Biotech News

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

GRI Bio (GRI)GRI Bio2026-04-08 08:30 ESTCompany update

Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation platform and expand strategic presence in a high-growth international market

LA JOLLA, CA, April 08, 2026 (GLOBE NEWSWIRE) -- <a...

Open original release

Related news

GRIGRI Bio2026-06-18 13:31 EST

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

GRIGRI Bio2026-05-14 08:35 EST

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline

BMYBMYBristol-Myers Squibb Company2026-05-08 10:59 EST

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults

SNGXSOLIGENIX2026-03-26 11:30 EST

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease

BMYBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

REGNRegeneron Pharmaceuticals2026-05-22 11:00 EST

Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss

SABSSAB Biotherapeutics2026-03-10 11:31 EST

SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes

SABSSAB Biotherapeutics2026-05-29 12:00 EST

SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

NRIXNurix Therapeutics2026-05-14 20:06 EST

Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting

KYMRKymera2026-04-13 11:00 EST

Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma

View all latest news

GRI Bio

BioRestorative or GRI is a historical small-cap biotech entry tied to biologics and regenerative or related platform work. Its story is best understood as an early-stage development attempt rather than a mature commercial franchise.

Recent company news

GRIGRI Bio2026-06-18 13:31 EST

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

GRIGRI Bio2026-05-14 08:35 EST

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline

GRIGRI Bio2026-04-08 08:30 EST

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

GRIGRI Bio2026-02-17 09:15 EST

GRI Bio CEO, Marc Hertz, Featured in Virtual Investor "What This Means" Segment

GRIGRI Bio2026-02-05 09:15 EST

GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Stock data

Close: 1.40 USD
Market cap: 3.56M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States